61 terminated. 61 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 61 | Terminated 61 |
| Phase 2 | 4 | Terminated 4 |
Follow Bronchial Diseases: new trials by email Literature Review of Bronchial Diseases trials Research Report on Bronchial Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension Clofazimine Inhalation Suspension, Placebo - MAC Lung Disease, Treatment Refractory MAC Lung Disease | Phase 3 | Terminated | Mannkind Corporation | 132 | 2024-09-11 | 2025-11-12 |
| Phase III Long-Term Extension Study With Dexpramipexole Dexpramipexole Dihydrochloride - Eosinophilic Asthma | Phase 3 | Terminated | Areteia Therapeutics | 509 | 2024-06-12 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 654 | 2023-03-27 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 1061 | 2023-01-30 | 2025-12-15 |
| Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma Tezepelumab, Placebo - Asthma | Phase 3 | Terminated | AstraZeneca | 125 | 2022-08-09 | 2026-06-18 |
| AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department Azithromycin, Placebo - Asthma, Wheezing | Phase 3 | Terminated | University of Arizona | 840 | 2021-11-22 | 2026-06-23 |
| A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat REGN1908-1909, Matching Placebo - Allergic Rhinitis Due to Cat Allergy | Phase 3 | Terminated | Regeneron Pharmaceuticals | 446 | 2021-07-30 | 2024-06-11 |
| A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) Experimental: CHF6001 1600µg, Experimental: CHF6001 3200µg, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 4710 | 2021-07-14 | 2025-12-17 |
| A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) CHF6001 1600µg, CHF6001 3200µg, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 3973 | 2021-07-12 | 2026-02-02 |
| Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation Seretide, Placebo - Stem Cell Transplant Complications, Respiratory Disease | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 35 | 2021-05-21 | 2025-09-16 |
| RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease RHB-204, Placebo - Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis | Phase 3 | Terminated | RedHill Biopharma Limited | 12 | 2020-12-01 | 2025-03-18 |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Pralsetinib, Carboplatin, Cisplatin - RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm | Phase 3 | Terminated | Hoffmann-La Roche | 223 | 2020-07-24 | 2026-03-05 |
| Protective Role of Inhaled Steroids for Covid-19 Infection 2: Usual practice + SYMBICORT RAPIHALER, 1: Usual practice - Covid-19 Infection, Hospitalization in Respiratory Disease Department | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 146 | 2020-04-13 | 2021-08-03 |
| Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3) Liposomal Cyclosporine A 5 mg, Liposomal Cyclosporine A 10 mg - Bronchiolitis Obliterans, Obliterative Bronchiolitis | Phase 3 | Terminated | Zambon SpA | 164 | 2020-03-12 | 2026-04-07 |
| Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy Brand Name: Flutiform K-haler - Asthma | Phase 3 | Terminated | Mundipharma Korea Ltd | 20 | 2019-11-26 | 2021-01-25 |
| Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID) Benralizumab 30 mg, Matched placebo - Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis | Phase 3 | Terminated | AstraZeneca | 295 | 2019-11-25 | 2026-02-19 |
| Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial Formoterol-beclomethasone, Placebo - Bronchiectasis | Phase 3 | Terminated | Erasmus Medical Center | 34 | 2019-01-29 | 2023-03-01 |
| GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Itacitinib, Placebo, Methylprednisolone - Chronic Graft-versus-host Disease | Phase 2 / Phase 3 | Terminated | Incyte Corporation | 155 | 2019-01-17 | 2025-10-20 |
| Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age Curosurf 80Mg/Ml Intratracheal Suspension, Ambient Air - Bronchiolitis, Viral | Phase 3 | Terminated | Azienda Ospedaliera Universitaria Integrata Verona | 9 | 2019-01-09 | 2021-04-15 |
| Systemic Corticosteroids Avoidance Study in Severe Asthma Patients Placebo once daily, QAW039 150 mg once daily, QAW039 450 mg once daily - Asthma | Phase 3 | Terminated | Novartis Pharmaceuticals | 604 | 2018-12-13 | 2021-10-11 |
Showing 20 of 61. Sign in to see all of them.
Asthma (34) · Bronchiolitis Obliterans Syndrome (11) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Bronchiolitis Obliterans (5) · Pain (5) · Bronchiectasis (4) · Bronchitis, Chronic (4) · Constipation (4) · Opioid-Induced Constipation (4) · Pulmonary Eosinophilia (4) · Carcinoma, Non-Small-Cell Lung (3) · Diabetes Mellitus, Type 1 (3) · Diabetes Mellitus, Type 2 (3)
Respiratory Tract Diseases (55) · Lung Diseases (53) · Lung Diseases, Obstructive (51) · Immune System Diseases (44) · Hypersensitivity, Immediate (34) · Hypersensitivity (33) · Respiratory Hypersensitivity (33) · Bronchitis (19) · Bronchiolitis (15) · Pathological Conditions, Signs and Symptoms (15) · Organizing Pneumonia (11) · Graft vs Host Disease (10) · Bronchiolitis Obliterans (9) · Infections (8)
Albuterol (5) · Paclitaxel (2) · Prednisone (2) · Saline Solution (2) · benralizumab (2) · fevipiprant (2) · 130-nm albumin-bound paclitaxel (1) · Anesthetics, Local (1) · Azithromycin (1) · Beclomethasone (1) · Betamethasone (1) · Budesonide (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Carboplatin (1) · Cisplatin (1)
AstraZeneca (5) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (4) · Amphastar Pharmaceuticals, Inc. (3) · Areteia Therapeutics (3) · Assistance Publique - Hôpitaux de Paris (3) · Mannkind Corporation (3) · Boehringer Ingelheim (2) · Chiesi Farmaceutici S.p.A. (2) · Hoffmann-La Roche (2) · Novartis Pharmaceuticals (2) · Pari Pharma GmbH (2) · Sumitomo Pharma America, Inc. (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · Zambon SpA (2) · APT Pharmaceuticals, Inc. (1)
United States (35) · Germany (20) · France (18) · Poland (18) · United Kingdom (17) · Spain (16) · Argentina (14) · Canada (13) · Belgium (12) · Czechia (12) · Italy (11) · Mexico (11) · Brazil (10) · Hungary (10) · Russia (10)
Brandon S Lu, MD, MS (1) · Bruce A Johnson, MD (1) · Carlos Barcina, MD (1) · Charlie Casper, PhD (1) · Claus Neurohr, MD (1) · Fernando D Martinez, MD (1)
PMID 39393433, PMID 17999759, PMID 29536781, PMID 29782642, PMID 30552284, PMID 32816215, PMID 33077567, PMID 33710614, PMID 34895218, PMID 35846226, PMID 36777695, PMID 36791280, PMID 38696034, PMID 42149992, PMID 42150582
2023 (5), 2016 (3), 2015 (2), 2018 (2), 2019 (2), 2005 (1), 2008 (1)